Anxiety and Depression Treatment Market By Offerings (Products (Benzodiazepine, Buspirone, Beta Blockers (Propranolol, Atenolol, Others), Others), Solutions, Services (Psychotherapy (Cognitive Behavioural Therapy (CBT), Interpersonal Therapy (IPT), Psychodynamic Therapy, Supportive Therapy, Others), Others); By Treatment Duration (Short Term, Long Term); By Form (Anxiety (Panic Disorder, Social Anxiety Disorder, Obsessive Compulsive Disorder, Generalized Anxiety Disorder, Others), Depression (Major Depression, Persistent Depressive Disorder, Bipolar Disorder, Others); By Distribution Channel (Online, Offline (Hospitals/Clinics, Wellness Centers, Research Centers, Others)); By Age Group (Children, Adults, Senior Citizens ); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Spain, Germany, Italy, Nordic Countries , Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia), Brazil, Argentina, Rest of Latin America, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 - 2028
Industry Trends
Depression has affected 350 million people worldwide and is projected to rise due to the upward trend in the acceptance of sedentary lifestyles. Depression is the world's second leading cause of impairment, increasing the need in the near future for the production of new drugs. In the global healthcare scenario, the prevalence of depression and anxiety has continued to increase. Such an increase in depression and anxiety occurrence rates has led to an emphasis on the global healthcare situation for the treatment of these disorders. In the global scenario, more than 300 million people of all ages suffered from depression in the year 2018. In the same year, there were 800,000 cases of suicides, the reasons behind the same were mostly depression and anxiety disorders. One of the major factors driving the Anxiety and Depression Treatment Market is this increase in the incidence rate of depression and anxiety.
A daunting part of practising medicine in the primary care environment is to better identify and treat patients with anxiety, depression, or both. Instead of classic psychological symptoms, patients frequently exhibit somatic complaints. Moreover, there is a substantial correlation between anxiety and depression. Anxiety and depression are major public health issues that affect a broad segment of the general population and account for multibillion-dollar spending directly related to health care and hospitalizations and indirectly related to morbidity and mortality. Depression and anxiety complaints are very common among adult patients seeking treatment in primary care settings, and the majority of drugs for these conditions are prescribed by primary care providers.
There are various causes for depression and anxiety, but they usually occur together. They have similar therapies as well. With psychiatric treatment medicine such as antidepressants symptoms in both conditions typically improve. Changes in lifestyles can help to reduce anxiety and depression.
Increased demand for antidepressants is leading to growth in adoption of these drugs and patient recovery due to reduced side effects associated with these drugs and rising levels of consumer knowledge. However, the rising rate of medication withdrawals and the launch of generic versions on a wide scale, patent expiration of most medications is expected to curb the growth of the demand for anxiety disorders and depression treatment in the coming years.
The dry pipeline for new drugs, drug-resistant psychiatric disorders and rising numbers of various generic drugs may hinder the growth of the demand for anxiety disorders and depression care. Also, it is expected that the launch of generic biosimilars by key players as a cost-effective alternative would hamper the growth of this Anxiety and Depression Treatment Market.
Market development is positively influenced by the existence of favourable reimbursement policies in developed regions for drugs and therapies. This has a positive effect on the market for medication for anxiety disorders. Help and education play an important role in the management of anxiety disorders alongside medications. Developing nations are coping tremendously with mental disorders for instance, every year in the U.S., about 10 million individuals suffer from mental illness. In addition, the growth of the Anxiety and Depression Treatment Market is further boosted by growing recognition and the increasing commitment of government organisations to alleviating the burden of disease. Global anxiety and depression treatment market was estimated to be US$ 18.5 Bn in 2019 and is expected to grow at a CAGR of 11.7% during the forecast period (2020-2028).
By Offerings
Anxiety and Depression Treatment Market participants have been working with public health entities in providing treatment for anxiety and depression to various patients. The treatment plan majorly includes medications, solutions, and services. Medications ranging from antidepressants, benzodiazepines, beta blockers and buspirone, among others. The medications are observed to impact the various transmitters that can be responsible for the onset of depression or help in reducing the impact of the mental disorders for the users. Software have been responsible for creating a channel between the professionals and the users for their consultations, and data transfer applications. Psychotherapy has been observed to be the notable offering in the market and is observed to have a higher rate of effectiveness across a wide range of users. The presence of the service in the short term and long term durations is expected to aid the growth of the market across various regions.
By Treatment Duration
The treatment for anxiety and depression is majorly dependent on the onset characteristics of the disorder for the patient. The medical professionals assess the severity of the disorder for various patients. This helps them in creating tailor made treatment plans for several patients. The patients are them provided with short term and long term treatment plans that would help in reducing the effects of disorders including anxiety and depression. Long term treatment duration is observed to be a greater revenue contributor for the Anxiety and Depression Treatment Market owing to higher investments from users in the treatment process.
By Form
Anxiety and depression are observed to be prevalent among various patients in an individual and mixed form over the years. Apart from the umbrella terms, there is an observation of disorders that are ranging from panic disorder, social anxiety disorder to persistent depressive disorder that have been prevalent across several countries. Increasing studies on the forms of mental disorders have been important for medical professionals in their process for developing treatment plans for a wide range of patients coming from numerous countries and from various age groups. The increasing number of forms in the anxiety and depression categories are also helping governing authorities to ramp up their awareness initiatives in order to reduce the impact of the disorders on the overall health of the general population in the near future. These efforts are expected to help in the development of comprehensive treatment processes which would lead to optimal recovery for the patients.
By Distribution Channel
The treatment for anxiety and depression has been designed to provide optimal relief for the patients across the world. Depending on the availability of services and solutions, treatment for anxiety and depression is imparted through the online and offline mode. Offline providers including hospitals/clinics, wellness centers and research centers have been responsible for offering in-person help to patients through psychotherapy and medications. In addition to this, in-home care services are also being developed that can help patients in their treatment phase. Online services were traditionally responsible to help patients during the procurement of medications prescribed by their medical professionals. With the advancements in mHealth and internet, various market participants have introduced online consultations and therapy sessions for several patients. In the conditions of lockdowns initiated due to the concerns related to the novel coronavirus (COVID-19), online services have been observed to receive significantly more requests for psychodynamic consultations and therapies. These factors are expected to help the market gain a wider customer base on the global scale.
By Age Group
The cases related to anxiety and depression have been observed to include patients across various age groups. Countries have been observing growth in the cases throughout the numerous age groups owing to the several reasons leading primarily towards mental disorders including anxiety and depression. Changes in the living conditions have been observed to be a major reason for the prevalence of mental disorders among children and adults. Senior citizens and adults contribute to a higher number of cases related to anxiety and depression on the global scale. In addition to this, the senior citizens are observed to suffer from anxiety and depression owing to reasons ranging from the relation between physical conditions to mental conditions, psychological trauma to substance issues among others. These factors are being studied in detail by medical researchers in order to develop an optimized treatment plan for the patients.
By Region
The awareness regarding anxiety and depression cases has been growing across various countries. The penetration of medical services has been observed to be more significant in developed countries as compared to developing countries. This has been responsible for the increasing prevalence of services and solutions related to anxiety and depression in various countries that are considered in the developed stages. Countries across regions including North America and Europe have shown positive trends in terms of the deployment of treatment solutions and services for patients suffering from anxiety and depression. Conducive initiatives from public and private organizations regarding the awareness for the various forms of mental disorders and the required treatment measures for the same have led to increasing adoption of Anxiety and Depression Treatment Market offerings across various regions. The region of Asia Pacific is expected to be a major adopter for market offerings owing to a steady rise in instances related to mental disorders along with initiatives undertaken by governing authorities across the countries for strengthening the healthcare infrastructure. These factors are expected to aid the growth of the Anxiety and Depression Treatment Market over the forecast period across various regions.
Anxiety and Depression Treatment Market Revenue & Forecast, (US$ Million), 2015 – 2028
Competitive Landscape
The report provides both, qualitative and quantitative research of anxiety and depression treatment market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the anxiety and depression treatment market are Actiza Pharmaceutical Private Limited, Amwell, ANI Pharmaceuticals, Inc., BetterHelp, eTherapyPro.com, F. Hoffmann-La Roche Ltd, Groop Internet Platform, Inc. (Talkspace), MDLIVE Inc., Pfizer Inc., Teva Pharmaceuticals USA, Inc., and The Ross Center, among others.
Anxiety and Depression Treatment Market:
By Offerings
- Products
- Benzodiazepine
- Buspirone
- Beta Blockers
- Propranolol
- Atenolol
- Others
- Others
- Solutions
- Services
- Psychotherapy
- Cognitive Behavioural Therapy (CBT)
- Interpersonal Therapy (IPT)
- Psychodynamic Therapy
- Supportive Therapy
- Others
- Others
By Treatment Duration
- Short Term
- Long Term
By Form
- Anxiety
- Panic Disorder
- Social Anxiety Disorder
- Obsessive Compulsive Disorder
- Generalized Anxiety Disorder
- Others
- Depression
- Major Depression
- Persistent Depressive Disorder
- Bipolar Disorder
- Others
By Distribution Channel
- Online
- Offline
- Hospitals/Clinics
- Wellness Centers
- Research Centers
- Others
By Age Group
- Children
- Adults
- Senior Citizens
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2018
1.2.2. Base
Year: 2019
1.2.3. Forecast
Years: 2020 – 2028
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Anxiety and Depression Treatment Market
6. Market Synopsis:
Anxiety and Depression Treatment Market
7. Anxiety and Depression Treatment Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Anxiety and Depression Treatment Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Anxiety and Depression Treatment Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
COVID-19 on Global Anxiety and Depression Treatment Market
8. Global Anxiety and Depression Treatment Market Analysis and
Forecasts, 2020 – 2028
8.1. Overview
8.1.1. Global
Anxiety and Depression Treatment Market Revenue (US$ Mn)
8.2. Global
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
8.2.1. Products
(Definition, Market Estimation and Penetration, 2015 – 2019, Market Estimation
(2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Benzodiazepine, Buspirone, Beta
Blockers, Others)
8.2.1.1. Benzodiazepine
8.2.1.2. Buspirone
8.2.1.3. Beta
Blockers
8.2.1.3.1. Propranolol
8.2.1.3.2. Atenolol
8.2.1.3.3. Others
8.2.1.4. Others
8.2.2. Solutions
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2019
8.2.2.3. Market
Forecast, 2020 – 2028
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2019
8.2.2.5.1.2. Market
Forecast, 2020 – 2028
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2019
8.2.2.5.2.2. Market
Forecast, 2020 – 2028
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2019
8.2.2.5.3.2. Market
Forecast, 2020 – 2028
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2019
8.2.2.5.4.2. Market
Forecast, 2020 – 2028
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2019
8.2.2.5.5.2. Market
Forecast, 2020 – 2028
8.2.3. Services
(Definition, Market Estimation and Penetration, 2015 – 2019, Market Estimation
(2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Psychotherapy, Others)
8.2.3.1. Psychotherapy
8.2.3.1.1. Cognitive
Behavioural Therapy (CBT)
8.2.3.1.2. Interpersonal
Therapy (IPT)
8.2.3.1.3. Psychodynamic
Therapy
8.2.3.1.4. Supportive
Therapy
8.2.3.1.5. Others
8.2.3.2. Others
8.3. Key
Segment for Channeling Investments
8.3.1. By
Offerings
9. Global Anxiety and Depression Treatment Market Analysis and
Forecasts, 2020 – 2028
9.1. Overview
9.2. Global
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
9.2.1. Short
Term
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2019
9.2.1.3. Market
Forecast, 2020 – 2028
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2019
9.2.1.5.1.2. Market
Forecast, 2020 – 2028
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2019
9.2.1.5.2.2. Market
Forecast, 2020 – 2028
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2019
9.2.1.5.3.2. Market
Forecast, 2020 – 2028
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2019
9.2.1.5.4.2. Market
Forecast, 2020 – 2028
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2019
9.2.1.5.5.2. Market
Forecast, 2020 – 2028
9.2.2. Long
Term
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2019
9.2.2.3. Market
Forecast, 2020 – 2028
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2019
9.2.2.5.1.2. Market
Forecast, 2020 – 2028
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2019
9.2.2.5.2.2. Market
Forecast, 2020 – 2028
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2019
9.2.2.5.3.2. Market
Forecast, 2020 – 2028
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2019
9.2.2.5.4.2. Market
Forecast, 2020 – 2028
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2019
9.2.2.5.5.2. Market
Forecast, 2020 – 2028
9.3. Key Segment
for Channeling Investments
9.3.1. By
Treatment Duration
10. Global Anxiety and Depression Treatment Market Analysis and
Forecasts, 2020 – 2028
10.1. Overview
10.2. Global
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
10.2.1. Anxiety
(Definition, Market Estimation and Penetration, 2015 – 2019, Market Estimation
(2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Panic Disorder, Social Anxiety
Disorder, Obsessive Compulsive Disorder, Generalized Anxiety Disorder, Others)
10.2.1.1. Panic
Disorder
10.2.1.2. Social
Anxiety Disorder
10.2.1.3. Obsessive
Compulsive Disorder
10.2.1.4. Generalized
Anxiety Disorder
10.2.1.5. Others
10.2.2. Depression
(Definition, Market Estimation and Penetration, 2015 – 2019, Market Estimation
(2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Major Depression, Persistent
Depressive Disorder, Bipolar Disorder, Others)
10.2.2.1. Major
Depression
10.2.2.2. Persistent
Depressive Disorder
10.2.2.3. Bipolar
Disorder
10.2.2.4. Others
10.3. Key
Segment for Channeling Investments
10.3.1. By Form
11. Global Anxiety and Depression Treatment Market Analysis and
Forecasts, 2020 – 2028
11.1. Overview
11.2. Global
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
11.2.1. Online
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2015 – 2019
11.2.1.3. Market
Forecast, 2020 – 2028
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2015 – 2019
11.2.1.5.1.2. Market
Forecast, 2020 – 2028
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2019
11.2.1.5.2.2. Market
Forecast, 2020 – 2028
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2019
11.2.1.5.3.2. Market
Forecast, 2020 – 2028
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2019
11.2.1.5.4.2. Market
Forecast, 2020 – 2028
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2015 – 2019
11.2.1.5.5.2. Market
Forecast, 2020 – 2028
11.2.2. Offline
(Definition, Market Estimation and Penetration, 2015 – 2019, Market Estimation
(2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Hospitals/Clinics, Wellness
Centers, Research Centers, Others)
11.2.2.1. Hospitals/Clinics
11.2.2.2. Wellness
Centers
11.2.2.3. Research
Centers
11.2.2.4. Others
11.3. Key
Segment for Channeling Investments
11.3.1. By
Distribution Channel
12. Global Anxiety and Depression Treatment Market Analysis and
Forecasts, 2020 – 2028
12.1. Overview
12.2. Global
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
12.2.1. Children
12.2.1.1. Definition
12.2.1.2. Market
Estimation and Penetration, 2015 – 2019
12.2.1.3. Market
Forecast, 2020 – 2028
12.2.1.4. Compound
Annual Growth Rate (CAGR)
12.2.1.5. Regional
Bifurcation
12.2.1.5.1. North
America
12.2.1.5.1.1. Market
Estimation, 2015 – 2019
12.2.1.5.1.2. Market
Forecast, 2020 – 2028
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2015 – 2019
12.2.1.5.2.2. Market
Forecast, 2020 – 2028
12.2.1.5.3. Asia
Pacific
12.2.1.5.3.1. Market
Estimation, 2015 – 2019
12.2.1.5.3.2. Market
Forecast, 2020 – 2028
12.2.1.5.4. Middle
East and Africa
12.2.1.5.4.1. Market
Estimation, 2015 – 2019
12.2.1.5.4.2. Market
Forecast, 2020 – 2028
12.2.1.5.5. Latin
America
12.2.1.5.5.1. Market
Estimation, 2015 – 2019
12.2.1.5.5.2. Market
Forecast, 2020 – 2028
12.2.2. Adults
12.2.2.1. Definition
12.2.2.2. Market
Estimation and Penetration, 2015 – 2019
12.2.2.3. Market
Forecast, 2020 – 2028
12.2.2.4. Compound
Annual Growth Rate (CAGR)
12.2.2.5. Regional
Bifurcation
12.2.2.5.1. North
America
12.2.2.5.1.1. Market
Estimation, 2015 – 2019
12.2.2.5.1.2. Market
Forecast, 2020 – 2028
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2015 – 2019
12.2.2.5.2.2. Market
Forecast, 2020 – 2028
12.2.2.5.3. Asia
Pacific
12.2.2.5.3.1. Market
Estimation, 2015 – 2019
12.2.2.5.3.2. Market
Forecast, 2020 – 2028
12.2.2.5.4. Middle
East and Africa
12.2.2.5.4.1. Market
Estimation, 2015 – 2019
12.2.2.5.4.2. Market
Forecast, 2020 – 2028
12.2.2.5.5. Latin
America
12.2.2.5.5.1. Market
Estimation, 2015 – 2019
12.2.2.5.5.2. Market
Forecast, 2020 – 2028
12.2.3. Senior
Citizens
12.2.3.1. Definition
12.2.3.2. Market
Estimation and Penetration, 2015 – 2019
12.2.3.3. Market
Forecast, 2020 – 2028
12.2.3.4. Compound
Annual Growth Rate (CAGR)
12.2.3.5. Regional
Bifurcation
12.2.3.5.1. North
America
12.2.3.5.1.1. Market
Estimation, 2015 – 2019
12.2.3.5.1.2. Market
Forecast, 2020 – 2028
12.2.3.5.2. Europe
12.2.3.5.2.1. Market
Estimation, 2015 – 2019
12.2.3.5.2.2. Market
Forecast, 2020 – 2028
12.2.3.5.3. Asia
Pacific
12.2.3.5.3.1. Market
Estimation, 2015 – 2019
12.2.3.5.3.2. Market
Forecast, 2020 – 2028
12.2.3.5.4. Middle
East and Africa
12.2.3.5.4.1. Market
Estimation, 2015 – 2019
12.2.3.5.4.2. Market
Forecast, 2020 – 2028
12.2.3.5.5. Latin
America
12.2.3.5.5.1. Market
Estimation, 2015 – 2019
12.2.3.5.5.2. Market
Forecast, 2020 – 2028
12.3. Key
Segment for Channeling Investments
12.3.1. By Age
Group
13. North America Anxiety and Depression Treatment Market
Analysis and Forecasts, 2020 - 2028
13.1. Overview
13.1.1. North
America Anxiety and Depression Treatment Market Revenue (US$ Mn)
13.2. North
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Offerings
13.2.1. Products
13.2.1.1. Benzodiazepine
13.2.1.2. Buspirone
13.2.1.3. Beta
Blockers
13.2.1.3.1. Propranolol
13.2.1.3.2. Atenolol
13.2.1.3.3. Others
13.2.1.4. Others
13.2.2. Solutions
13.2.3. Services
13.2.3.1. Psychotherapy
13.2.3.1.1. Cognitive
Behavioural Therapy (CBT)
13.2.3.1.2. Interpersonal
Therapy (IPT)
13.2.3.1.3. Psychodynamic
Therapy
13.2.3.1.4. Supportive
Therapy
13.2.3.1.5. Others
13.2.3.2. Others
13.3. North
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment Duration
13.3.1. Short
Term
13.3.2. Long
Term
13.4. North
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Form
13.4.1. Anxiety
13.4.1.1. Panic
Disorder
13.4.1.2. Social
Anxiety Disorder
13.4.1.3. Obsessive
Compulsive Disorder
13.4.1.4. Generalized
Anxiety Disorder
13.4.1.5. Others
13.4.2. Depression
13.4.2.1. Major
Depression
13.4.2.2. Persistent
Depressive Disorder
13.4.2.3. Bipolar
Disorder
13.4.2.4. Others
13.5. North
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
13.5.1. Online
13.5.2. Offline
13.5.2.1. Hospitals/Clinics
13.5.2.2. Wellness
Centers
13.5.2.3. Research
Centers
13.5.2.4. Others
13.6. North
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Age Group
13.6.1. Children
13.6.2. Adults
13.6.3. Senior
Citizens
13.7. North
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Country
13.7.1. U.S
13.7.1.1. U.S
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
13.7.1.1.1. Products
13.7.1.1.1.1. Benzodiazepine
13.7.1.1.1.2. Buspirone
13.7.1.1.1.3. Beta
Blockers
13.7.1.1.1.3.1. Propranolol
13.7.1.1.1.3.2. Atenolol
13.7.1.1.1.3.3. Others
13.7.1.1.1.4. Others
13.7.1.1.2. Solutions
13.7.1.1.3. Services
13.7.1.1.3.1. Psychotherapy
13.7.1.1.3.1.1. Cognitive Behavioural Therapy (CBT)
13.7.1.1.3.1.2. Interpersonal Therapy (IPT)
13.7.1.1.3.1.3. Psychodynamic Therapy
13.7.1.1.3.1.4. Supportive Therapy
13.7.1.1.3.1.5. Others
13.7.1.1.3.2. Others
13.7.1.2. U.S
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
13.7.1.2.1. Short
Term
13.7.1.2.2. Long
Term
13.7.1.3. U.S
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
13.7.1.3.1. Anxiety
13.7.1.3.1.1. Panic
Disorder
13.7.1.3.1.2. Social
Anxiety Disorder
13.7.1.3.1.3. Obsessive
Compulsive Disorder
13.7.1.3.1.4. Generalized
Anxiety Disorder
13.7.1.3.1.5. Others
13.7.1.3.2. Depression
13.7.1.3.2.1. Major
Depression
13.7.1.3.2.2. Persistent
Depressive Disorder
13.7.1.3.2.3. Bipolar
Disorder
13.7.1.3.2.4. Others
13.7.1.4. U.S
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.7.1.4.1. Online
13.7.1.4.2. Offline
13.7.1.4.2.1. Hospitals/Clinics
13.7.1.4.2.2. Wellness
Centers
13.7.1.4.2.3. Research
Centers
13.7.1.4.2.4. Others
13.7.1.5. U.S
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
13.7.1.5.1. Children
13.7.1.5.2. Adults
13.7.1.5.3. Senior
Citizens
13.7.2. Canada
13.7.2.1. Canada
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
13.7.2.1.1. Products
13.7.2.1.1.1. Benzodiazepine
13.7.2.1.1.2. Buspirone
13.7.2.1.1.3. Beta
Blockers
13.7.2.1.1.3.1. Propranolol
13.7.2.1.1.3.2. Atenolol
13.7.2.1.1.3.3. Others
13.7.2.1.1.4. Others
13.7.2.1.2. Solutions
13.7.2.1.3. Services
13.7.2.1.3.1. Psychotherapy
13.7.2.1.3.1.1. Cognitive Behavioural Therapy (CBT)
13.7.2.1.3.1.2. Interpersonal Therapy (IPT)
13.7.2.1.3.1.3. Psychodynamic Therapy
13.7.2.1.3.1.4. Supportive Therapy
13.7.2.1.3.1.5. Others
13.7.2.1.3.2. Others
13.7.2.2. Canada
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
13.7.2.2.1. Short
Term
13.7.2.2.2. Long
Term
13.7.2.3. Canada
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
13.7.2.3.1. Anxiety
13.7.2.3.1.1. Panic
Disorder
13.7.2.3.1.2. Social
Anxiety Disorder
13.7.2.3.1.3. Obsessive
Compulsive Disorder
13.7.2.3.1.4. Generalized
Anxiety Disorder
13.7.2.3.1.5. Others
13.7.2.3.2. Depression
13.7.2.3.2.1. Major
Depression
13.7.2.3.2.2. Persistent
Depressive Disorder
13.7.2.3.2.3. Bipolar
Disorder
13.7.2.3.2.4. Others
13.7.2.4. Canada
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.7.2.4.1. Online
13.7.2.4.2. Offline
13.7.2.4.2.1. Hospitals/Clinics
13.7.2.4.2.2. Wellness
Centers
13.7.2.4.2.3. Research
Centers
13.7.2.4.2.4. Others
13.7.2.5. Canada
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
13.7.2.5.1. Children
13.7.2.5.2. Adults
13.7.2.5.3. Senior
Citizens
13.7.3. Mexico
13.7.3.1. Mexico
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
13.7.3.1.1. Products
13.7.3.1.1.1. Benzodiazepine
13.7.3.1.1.2. Buspirone
13.7.3.1.1.3. Beta
Blockers
13.7.3.1.1.3.1. Propranolol
13.7.3.1.1.3.2. Atenolol
13.7.3.1.1.3.3. Others
13.7.3.1.1.4. Others
13.7.3.1.2. Solutions
13.7.3.1.3. Services
13.7.3.1.3.1. Psychotherapy
13.7.3.1.3.1.1. Cognitive Behavioural Therapy (CBT)
13.7.3.1.3.1.2. Interpersonal Therapy (IPT)
13.7.3.1.3.1.3. Psychodynamic Therapy
13.7.3.1.3.1.4. Supportive Therapy
13.7.3.1.3.1.5. Others
13.7.3.1.3.2. Others
13.7.3.2. Mexico
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
13.7.3.2.1. Short
Term
13.7.3.2.2. Long
Term
13.7.3.3. Mexico
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
13.7.3.3.1. Anxiety
13.7.3.3.1.1. Panic
Disorder
13.7.3.3.1.2. Social
Anxiety Disorder
13.7.3.3.1.3. Obsessive
Compulsive Disorder
13.7.3.3.1.4. Generalized
Anxiety Disorder
13.7.3.3.1.5. Others
13.7.3.3.2. Depression
13.7.3.3.2.1. Major
Depression
13.7.3.3.2.2. Persistent
Depressive Disorder
13.7.3.3.2.3. Bipolar
Disorder
13.7.3.3.2.4. Others
13.7.3.4. Mexico
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.7.3.4.1. Online
13.7.3.4.2. Offline
13.7.3.4.2.1. Hospitals/Clinics
13.7.3.4.2.2. Wellness
Centers
13.7.3.4.2.3. Research
Centers
13.7.3.4.2.4. Others
13.7.3.5. Mexico
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
13.7.3.5.1. Children
13.7.3.5.2. Adults
13.7.3.5.3. Senior
Citizens
13.7.4. Rest of
North America
13.7.4.1. Rest
of North America Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Offerings
13.7.4.1.1. Products
13.7.4.1.1.1. Benzodiazepine
13.7.4.1.1.2. Buspirone
13.7.4.1.1.3. Beta
Blockers
13.7.4.1.1.3.1. Propranolol
13.7.4.1.1.3.2. Atenolol
13.7.4.1.1.3.3. Others
13.7.4.1.1.4. Others
13.7.4.1.2. Solutions
13.7.4.1.3. Services
13.7.4.1.3.1. Psychotherapy
13.7.4.1.3.1.1. Cognitive Behavioural Therapy (CBT)
13.7.4.1.3.1.2. Interpersonal Therapy (IPT)
13.7.4.1.3.1.3. Psychodynamic Therapy
13.7.4.1.3.1.4. Supportive Therapy
13.7.4.1.3.1.5. Others
13.7.4.1.3.2. Others
13.7.4.2. Rest
of North America Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment Duration
13.7.4.2.1. Short
Term
13.7.4.2.2. Long
Term
13.7.4.3. Rest
of North America Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Form
13.7.4.3.1. Anxiety
13.7.4.3.1.1. Panic
Disorder
13.7.4.3.1.2. Social
Anxiety Disorder
13.7.4.3.1.3. Obsessive
Compulsive Disorder
13.7.4.3.1.4. Generalized
Anxiety Disorder
13.7.4.3.1.5. Others
13.7.4.3.2. Depression
13.7.4.3.2.1. Major
Depression
13.7.4.3.2.2. Persistent
Depressive Disorder
13.7.4.3.2.3. Bipolar
Disorder
13.7.4.3.2.4. Others
13.7.4.4. Rest
of North America Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.7.4.4.1. Online
13.7.4.4.2. Offline
13.7.4.4.2.1. Hospitals/Clinics
13.7.4.4.2.2. Wellness
Centers
13.7.4.4.2.3. Research
Centers
13.7.4.4.2.4. Others
13.7.4.5. Rest
of North America Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Age Group
13.7.4.5.1. Children
13.7.4.5.2. Adults
13.7.4.5.3. Senior
Citizens
13.8. Key
Segment for Channeling Investments
13.8.1. By
Country
13.8.2. By
Offerings
13.8.3. By
Treatment Duration
13.8.4. By Form
13.8.5. By
Distribution Channel
13.8.6. By Age
Group
14. Europe Anxiety and Depression Treatment Market Analysis and
Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Europe
Anxiety and Depression Treatment Market Revenue (US$ Mn)
14.2. Europe
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
14.2.1. Products
14.2.1.1. Benzodiazepine
14.2.1.2. Buspirone
14.2.1.3. Beta
Blockers
14.2.1.3.1. Propranolol
14.2.1.3.2. Atenolol
14.2.1.3.3. Others
14.2.1.4. Others
14.2.2. Solutions
14.2.3. Services
14.2.3.1. Psychotherapy
14.2.3.1.1. Cognitive
Behavioural Therapy (CBT)
14.2.3.1.2. Interpersonal
Therapy (IPT)
14.2.3.1.3. Psychodynamic
Therapy
14.2.3.1.4. Supportive
Therapy
14.2.3.1.5. Others
14.2.3.2. Others
14.3. Europe Anxiety
and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment
Duration
14.3.1. Short
Term
14.3.2. Long
Term
14.4. Europe
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
14.4.1. Anxiety
14.4.1.1. Panic
Disorder
14.4.1.2. Social
Anxiety Disorder
14.4.1.3. Obsessive
Compulsive Disorder
14.4.1.4. Generalized
Anxiety Disorder
14.4.1.5. Others
14.4.2. Depression
14.4.2.1. Major
Depression
14.4.2.2. Persistent
Depressive Disorder
14.4.2.3. Bipolar
Disorder
14.4.2.4. Others
14.5. Europe
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.5.1. Online
14.5.2. Offline
14.5.2.1. Hospitals/Clinics
14.5.2.2. Wellness
Centers
14.5.2.3. Research
Centers
14.5.2.4. Others
14.6. Europe
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
14.6.1. Children
14.6.2. Adults
14.6.3. Senior
Citizens
14.7. Europe
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.1. France
14.7.1.1. France
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
14.7.1.1.1. Products
14.7.1.1.1.1. Benzodiazepine
14.7.1.1.1.2. Buspirone
14.7.1.1.1.3. Beta
Blockers
14.7.1.1.1.3.1. Propranolol
14.7.1.1.1.3.2. Atenolol
14.7.1.1.1.3.3. Others
14.7.1.1.1.4. Others
14.7.1.1.2. Solutions
14.7.1.1.3. Services
14.7.1.1.3.1. Psychotherapy
14.7.1.1.3.1.1. Cognitive Behavioural Therapy (CBT)
14.7.1.1.3.1.2. Interpersonal Therapy (IPT)
14.7.1.1.3.1.3. Psychodynamic Therapy
14.7.1.1.3.1.4. Supportive Therapy
14.7.1.1.3.1.5. Others
14.7.1.1.3.2. Others
14.7.1.2. France
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
14.7.1.2.1. Short
Term
14.7.1.2.2. Long
Term
14.7.1.3. France
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
14.7.1.3.1. Anxiety
14.7.1.3.1.1. Panic
Disorder
14.7.1.3.1.2. Social
Anxiety Disorder
14.7.1.3.1.3. Obsessive
Compulsive Disorder
14.7.1.3.1.4. Generalized
Anxiety Disorder
14.7.1.3.1.5. Others
14.7.1.3.2. Depression
14.7.1.3.2.1. Major
Depression
14.7.1.3.2.2. Persistent
Depressive Disorder
14.7.1.3.2.3. Bipolar
Disorder
14.7.1.3.2.4. Others
14.7.1.4. France
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.7.1.4.1. Online
14.7.1.4.2. Offline
14.7.1.4.2.1. Hospitals/Clinics
14.7.1.4.2.2. Wellness
Centers
14.7.1.4.2.3. Research
Centers
14.7.1.4.2.4. Others
14.7.1.5. France
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
14.7.1.5.1. Children
14.7.1.5.2. Adults
14.7.1.5.3. Senior
Citizens
14.7.2. The UK
14.7.2.1. The
UK Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
14.7.2.1.1. Products
14.7.2.1.1.1. Benzodiazepine
14.7.2.1.1.2. Buspirone
14.7.2.1.1.3. Beta
Blockers
14.7.2.1.1.3.1. Propranolol
14.7.2.1.1.3.2. Atenolol
14.7.2.1.1.3.3. Others
14.7.2.1.1.4. Others
14.7.2.1.2. Solutions
14.7.2.1.3. Services
14.7.2.1.3.1. Psychotherapy
14.7.2.1.3.1.1. Cognitive Behavioural Therapy (CBT)
14.7.2.1.3.1.2. Interpersonal Therapy (IPT)
14.7.2.1.3.1.3. Psychodynamic Therapy
14.7.2.1.3.1.4. Supportive Therapy
14.7.2.1.3.1.5. Others
14.7.2.1.3.2. Others
14.7.2.2. The
UK Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
14.7.2.2.1. Short
Term
14.7.2.2.2. Long
Term
14.7.2.3. The
UK Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Form
14.7.2.3.1. Anxiety
14.7.2.3.1.1. Panic
Disorder
14.7.2.3.1.2. Social
Anxiety Disorder
14.7.2.3.1.3. Obsessive
Compulsive Disorder
14.7.2.3.1.4. Generalized
Anxiety Disorder
14.7.2.3.1.5. Others
14.7.2.3.2. Depression
14.7.2.3.2.1. Major
Depression
14.7.2.3.2.2. Persistent
Depressive Disorder
14.7.2.3.2.3. Bipolar
Disorder
14.7.2.3.2.4. Others
14.7.2.4. The
UK Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.7.2.4.1. Online
14.7.2.4.2. Offline
14.7.2.4.2.1. Hospitals/Clinics
14.7.2.4.2.2. Wellness
Centers
14.7.2.4.2.3. Research
Centers
14.7.2.4.2.4. Others
14.7.2.5. The
UK Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Age Group
14.7.2.5.1. Children
14.7.2.5.2. Adults
14.7.2.5.3. Senior
Citizens
14.7.3. Spain
14.7.3.1. Spain
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
14.7.3.1.1. Products
14.7.3.1.1.1. Benzodiazepine
14.7.3.1.1.2. Buspirone
14.7.3.1.1.3. Beta
Blockers
14.7.3.1.1.3.1. Propranolol
14.7.3.1.1.3.2. Atenolol
14.7.3.1.1.3.3. Others
14.7.3.1.1.4. Others
14.7.3.1.2. Solutions
14.7.3.1.3. Services
14.7.3.1.3.1. Psychotherapy
14.7.3.1.3.1.1. Cognitive Behavioural Therapy (CBT)
14.7.3.1.3.1.2. Interpersonal Therapy (IPT)
14.7.3.1.3.1.3. Psychodynamic Therapy
14.7.3.1.3.1.4. Supportive Therapy
14.7.3.1.3.1.5. Others
14.7.3.1.3.2. Others
14.7.3.2. Spain
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
14.7.3.2.1. Short
Term
14.7.3.2.2. Long
Term
14.7.3.3. Spain
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
14.7.3.3.1. Anxiety
14.7.3.3.1.1. Panic
Disorder
14.7.3.3.1.2. Social
Anxiety Disorder
14.7.3.3.1.3. Obsessive
Compulsive Disorder
14.7.3.3.1.4. Generalized
Anxiety Disorder
14.7.3.3.1.5. Others
14.7.3.3.2. Depression
14.7.3.3.2.1. Major
Depression
14.7.3.3.2.2. Persistent
Depressive Disorder
14.7.3.3.2.3. Bipolar
Disorder
14.7.3.3.2.4. Others
14.7.3.4. Spain
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.7.3.4.1. Online
14.7.3.4.2. Offline
14.7.3.4.2.1. Hospitals/Clinics
14.7.3.4.2.2. Wellness
Centers
14.7.3.4.2.3. Research
Centers
14.7.3.4.2.4. Others
14.7.3.5. Spain
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
14.7.3.5.1. Children
14.7.3.5.2. Adults
14.7.3.5.3. Senior
Citizens
14.7.4. Germany
14.7.4.1. Germany
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
14.7.4.1.1. Products
14.7.4.1.1.1. Benzodiazepine
14.7.4.1.1.2. Buspirone
14.7.4.1.1.3. Beta
Blockers
14.7.4.1.1.3.1. Propranolol
14.7.4.1.1.3.2. Atenolol
14.7.4.1.1.3.3. Others
14.7.4.1.1.4. Others
14.7.4.1.2. Solutions
14.7.4.1.3. Services
14.7.4.1.3.1. Psychotherapy
14.7.4.1.3.1.1. Cognitive Behavioural Therapy (CBT)
14.7.4.1.3.1.2. Interpersonal Therapy (IPT)
14.7.4.1.3.1.3. Psychodynamic Therapy
14.7.4.1.3.1.4. Supportive Therapy
14.7.4.1.3.1.5. Others
14.7.4.1.3.2. Others
14.7.4.2. Germany
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
14.7.4.2.1. Short
Term
14.7.4.2.2. Long
Term
14.7.4.3. Germany
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
14.7.4.3.1. Anxiety
14.7.4.3.1.1. Panic
Disorder
14.7.4.3.1.2. Social
Anxiety Disorder
14.7.4.3.1.3. Obsessive
Compulsive Disorder
14.7.4.3.1.4. Generalized
Anxiety Disorder
14.7.4.3.1.5. Others
14.7.4.3.2. Depression
14.7.4.3.2.1. Major
Depression
14.7.4.3.2.2. Persistent
Depressive Disorder
14.7.4.3.2.3. Bipolar
Disorder
14.7.4.3.2.4. Others
14.7.4.4. Germany
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.7.4.4.1. Online
14.7.4.4.2. Offline
14.7.4.4.2.1. Hospitals/Clinics
14.7.4.4.2.2. Wellness
Centers
14.7.4.4.2.3. Research
Centers
14.7.4.4.2.4. Others
14.7.4.5. Germany
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
14.7.4.5.1. Children
14.7.4.5.2. Adults
14.7.4.5.3. Senior
Citizens
14.7.5. Italy
14.7.5.1. Italy
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
14.7.5.1.1. Products
14.7.5.1.1.1. Benzodiazepine
14.7.5.1.1.2. Buspirone
14.7.5.1.1.3. Beta
Blockers
14.7.5.1.1.3.1. Propranolol
14.7.5.1.1.3.2. Atenolol
14.7.5.1.1.3.3. Others
14.7.5.1.1.4. Others
14.7.5.1.2. Solutions
14.7.5.1.3. Services
14.7.5.1.3.1. Psychotherapy
14.7.5.1.3.1.1. Cognitive Behavioural Therapy (CBT)
14.7.5.1.3.1.2. Interpersonal Therapy (IPT)
14.7.5.1.3.1.3. Psychodynamic Therapy
14.7.5.1.3.1.4. Supportive Therapy
14.7.5.1.3.1.5. Others
14.7.5.1.3.2. Others
14.7.5.2. Italy
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
14.7.5.2.1. Short
Term
14.7.5.2.2. Long
Term
14.7.5.3. Italy
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
14.7.5.3.1. Anxiety
14.7.5.3.1.1. Panic
Disorder
14.7.5.3.1.2. Social
Anxiety Disorder
14.7.5.3.1.3. Obsessive
Compulsive Disorder
14.7.5.3.1.4. Generalized
Anxiety Disorder
14.7.5.3.1.5. Others
14.7.5.3.2. Depression
14.7.5.3.2.1. Major
Depression
14.7.5.3.2.2. Persistent
Depressive Disorder
14.7.5.3.2.3. Bipolar
Disorder
14.7.5.3.2.4. Others
14.7.5.4. Italy
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.7.5.4.1. Online
14.7.5.4.2. Offline
14.7.5.4.2.1. Hospitals/Clinics
14.7.5.4.2.2. Wellness
Centers
14.7.5.4.2.3. Research
Centers
14.7.5.4.2.4. Others
14.7.5.5. Italy
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
14.7.5.5.1. Children
14.7.5.5.2. Adults
14.7.5.5.3. Senior
Citizens
14.7.6. Nordic
Countries
14.7.6.1. Nordic
Countries Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Offerings
14.7.6.1.1. Products
14.7.6.1.1.1. Benzodiazepine
14.7.6.1.1.2. Buspirone
14.7.6.1.1.3. Beta
Blockers
14.7.6.1.1.3.1. Propranolol
14.7.6.1.1.3.2. Atenolol
14.7.6.1.1.3.3. Others
14.7.6.1.1.4. Others
14.7.6.1.2. Solutions
14.7.6.1.3. Services
14.7.6.1.3.1. Psychotherapy
14.7.6.1.3.1.1. Cognitive Behavioural Therapy (CBT)
14.7.6.1.3.1.2. Interpersonal Therapy (IPT)
14.7.6.1.3.1.3. Psychodynamic Therapy
14.7.6.1.3.1.4. Supportive Therapy
14.7.6.1.3.1.5. Others
14.7.6.1.3.2. Others
14.7.6.2. Nordic
Countries Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment Duration
14.7.6.2.1. Short
Term
14.7.6.2.2. Long
Term
14.7.6.3. Nordic
Countries Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Form
14.7.6.3.1. Anxiety
14.7.6.3.1.1. Panic
Disorder
14.7.6.3.1.2. Social
Anxiety Disorder
14.7.6.3.1.3. Obsessive
Compulsive Disorder
14.7.6.3.1.4. Generalized
Anxiety Disorder
14.7.6.3.1.5. Others
14.7.6.3.2. Depression
14.7.6.3.2.1. Major
Depression
14.7.6.3.2.2. Persistent
Depressive Disorder
14.7.6.3.2.3. Bipolar
Disorder
14.7.6.3.2.4. Others
14.7.6.4. Nordic
Countries Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.7.6.4.1. Online
14.7.6.4.2. Offline
14.7.6.4.2.1. Hospitals/Clinics
14.7.6.4.2.2. Wellness
Centers
14.7.6.4.2.3. Research
Centers
14.7.6.4.2.4. Others
14.7.6.5. Nordic
Countries Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Age Group
14.7.6.5.1. Children
14.7.6.5.2. Adults
14.7.6.5.3. Senior
Citizens
14.7.6.6. Nordic
Countries Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux
Union
14.7.7.1. Benelux
Union Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Offerings
14.7.7.1.1. Products
14.7.7.1.1.1. Benzodiazepine
14.7.7.1.1.2. Buspirone
14.7.7.1.1.3. Beta
Blockers
14.7.7.1.1.3.1. Propranolol
14.7.7.1.1.3.2. Atenolol
14.7.7.1.1.3.3. Others
14.7.7.1.1.4. Others
14.7.7.1.2. Solutions
14.7.7.1.3. Services
14.7.7.1.3.1. Psychotherapy
14.7.7.1.3.1.1. Cognitive Behavioural Therapy (CBT)
14.7.7.1.3.1.2. Interpersonal Therapy (IPT)
14.7.7.1.3.1.3. Psychodynamic Therapy
14.7.7.1.3.1.4. Supportive Therapy
14.7.7.1.3.1.5. Others
14.7.7.1.3.2. Others
14.7.7.2. Benelux
Union Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment Duration
14.7.7.2.1. Short
Term
14.7.7.2.2. Long
Term
14.7.7.3. Benelux
Union Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Form
14.7.7.3.1. Anxiety
14.7.7.3.1.1. Panic
Disorder
14.7.7.3.1.2. Social
Anxiety Disorder
14.7.7.3.1.3. Obsessive
Compulsive Disorder
14.7.7.3.1.4. Generalized
Anxiety Disorder
14.7.7.3.1.5. Others
14.7.7.3.2. Depression
14.7.7.3.2.1. Major
Depression
14.7.7.3.2.2. Persistent
Depressive Disorder
14.7.7.3.2.3. Bipolar
Disorder
14.7.7.3.2.4. Others
14.7.7.4. Benelux
Union Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
14.7.7.4.1. Online
14.7.7.4.2. Offline
14.7.7.4.2.1. Hospitals/Clinics
14.7.7.4.2.2. Wellness
Centers
14.7.7.4.2.3. Research
Centers
14.7.7.4.2.4. Others
14.7.7.5. Benelux
Union Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Age Group
14.7.7.5.1. Children
14.7.7.5.2. Adults
14.7.7.5.3. Senior
Citizens
14.7.7.6. Benelux
Union Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The
Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of
Europe
14.7.8.1. Rest
of Europe Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Offerings
14.7.8.1.1. Products
14.7.8.1.1.1. Benzodiazepine
14.7.8.1.1.2. Buspirone
14.7.8.1.1.3. Beta
Blockers
14.7.8.1.1.3.1. Propranolol
14.7.8.1.1.3.2. Atenolol
14.7.8.1.1.3.3. Others
14.7.8.1.1.4. Others
14.7.8.1.2. Solutions
14.7.8.1.3. Services
14.7.8.1.3.1. Psychotherapy
14.7.8.1.3.1.1. Cognitive Behavioural Therapy (CBT)
14.7.8.1.3.1.2. Interpersonal Therapy (IPT)
14.7.8.1.3.1.3. Psychodynamic Therapy
14.7.8.1.3.1.4. Supportive Therapy
14.7.8.1.3.1.5. Others
14.7.8.1.3.2. Others
14.7.8.2. Rest
of Europe Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment Duration
14.7.8.2.1. Short
Term
14.7.8.2.2. Long
Term
14.7.8.3. Rest
of Europe Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Form
14.7.8.3.1. Anxiety
14.7.8.3.1.1. Panic
Disorder
14.7.8.3.1.2. Social
Anxiety Disorder
14.7.8.3.1.3. Obsessive
Compulsive Disorder
14.7.8.3.1.4. Generalized
Anxiety Disorder
14.7.8.3.1.5. Others
14.7.8.3.2. Depression
14.7.8.3.2.1. Major
Depression
14.7.8.3.2.2. Persistent
Depressive Disorder
14.7.8.3.2.3. Bipolar
Disorder
14.7.8.3.2.4. Others
14.7.8.4. Rest
of Europe Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.7.8.4.1. Online
14.7.8.4.2. Offline
14.7.8.4.2.1. Hospitals/Clinics
14.7.8.4.2.2. Wellness
Centers
14.7.8.4.2.3. Research
Centers
14.7.8.4.2.4. Others
14.7.8.5. Rest
of Europe Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Age Group
14.7.8.5.1. Children
14.7.8.5.2. Adults
14.7.8.5.3. Senior
Citizens
14.8. Key
Segment for Channeling Investments
14.8.1. By
Country
14.8.2. By
Offerings
14.8.3. By
Treatment Duration
14.8.4. By Form
14.8.5. By
Distribution Channel
14.8.6. By Age
Group
15. Asia Pacific Anxiety and Depression Treatment Market Analysis
and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Asia
Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn)
15.2. Asia
Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Offerings
15.2.1. Products
15.2.1.1. Benzodiazepine
15.2.1.2. Buspirone
15.2.1.3. Beta
Blockers
15.2.1.3.1. Propranolol
15.2.1.3.2. Atenolol
15.2.1.3.3. Others
15.2.1.4. Others
15.2.2. Solutions
15.2.3. Services
15.2.3.1. Psychotherapy
15.2.3.1.1. Cognitive
Behavioural Therapy (CBT)
15.2.3.1.2. Interpersonal
Therapy (IPT)
15.2.3.1.3. Psychodynamic
Therapy
15.2.3.1.4. Supportive
Therapy
15.2.3.1.5. Others
15.2.3.2. Others
15.3. Asia
Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment Duration
15.3.1. Short
Term
15.3.2. Long
Term
15.4. Asia
Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Form
15.4.1. Anxiety
15.4.1.1. Panic
Disorder
15.4.1.2. Social
Anxiety Disorder
15.4.1.3. Obsessive
Compulsive Disorder
15.4.1.4. Generalized
Anxiety Disorder
15.4.1.5. Others
15.4.2. Depression
15.4.2.1. Major
Depression
15.4.2.2. Persistent
Depressive Disorder
15.4.2.3. Bipolar
Disorder
15.4.2.4. Others
15.5. Asia
Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
15.5.1. Online
15.5.2. Offline
15.5.2.1. Hospitals/Clinics
15.5.2.2. Wellness
Centers
15.5.2.3. Research
Centers
15.5.2.4. Others
15.6. Asia
Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Age Group
15.6.1. Children
15.6.2. Adults
15.6.3. Senior
Citizens
15.7. Asia
Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Country
15.7.1. China
15.7.1.1. China
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
15.7.1.1.1. Products
15.7.1.1.1.1. Benzodiazepine
15.7.1.1.1.2. Buspirone
15.7.1.1.1.3. Beta
Blockers
15.7.1.1.1.3.1. Propranolol
15.7.1.1.1.3.2. Atenolol
15.7.1.1.1.3.3. Others
15.7.1.1.1.4. Others
15.7.1.1.2. Solutions
15.7.1.1.3. Services
15.7.1.1.3.1. Psychotherapy
15.7.1.1.3.1.1. Cognitive Behavioural Therapy (CBT)
15.7.1.1.3.1.2. Interpersonal Therapy (IPT)
15.7.1.1.3.1.3. Psychodynamic Therapy
15.7.1.1.3.1.4. Supportive Therapy
15.7.1.1.3.1.5. Others
15.7.1.1.3.2. Others
15.7.1.2. China
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
15.7.1.2.1. Short
Term
15.7.1.2.2. Long
Term
15.7.1.3. China
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
15.7.1.3.1. Anxiety
15.7.1.3.1.1. Panic
Disorder
15.7.1.3.1.2. Social
Anxiety Disorder
15.7.1.3.1.3. Obsessive
Compulsive Disorder
15.7.1.3.1.4. Generalized
Anxiety Disorder
15.7.1.3.1.5. Others
15.7.1.3.2. Depression
15.7.1.3.2.1. Major
Depression
15.7.1.3.2.2. Persistent
Depressive Disorder
15.7.1.3.2.3. Bipolar
Disorder
15.7.1.3.2.4. Others
15.7.1.4. China
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.7.1.4.1. Online
15.7.1.4.2. Offline
15.7.1.4.2.1. Hospitals/Clinics
15.7.1.4.2.2. Wellness
Centers
15.7.1.4.2.3. Research
Centers
15.7.1.4.2.4. Others
15.7.1.5. China
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
15.7.1.5.1. Children
15.7.1.5.2. Adults
15.7.1.5.3. Senior
Citizens
15.7.2. Japan
15.7.2.1. Japan
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
15.7.2.1.1. Products
15.7.2.1.1.1. Benzodiazepine
15.7.2.1.1.2. Buspirone
15.7.2.1.1.3. Beta
Blockers
15.7.2.1.1.3.1. Propranolol
15.7.2.1.1.3.2. Atenolol
15.7.2.1.1.3.3. Others
15.7.2.1.1.4. Others
15.7.2.1.2. Solutions
15.7.2.1.3. Services
15.7.2.1.3.1. Psychotherapy
15.7.2.1.3.1.1. Cognitive Behavioural Therapy (CBT)
15.7.2.1.3.1.2. Interpersonal Therapy (IPT)
15.7.2.1.3.1.3. Psychodynamic Therapy
15.7.2.1.3.1.4. Supportive Therapy
15.7.2.1.3.1.5. Others
15.7.2.1.3.2. Others
15.7.2.2. Japan
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
15.7.2.2.1. Short
Term
15.7.2.2.2. Long
Term
15.7.2.3. Japan
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
15.7.2.3.1. Anxiety
15.7.2.3.1.1. Panic
Disorder
15.7.2.3.1.2. Social
Anxiety Disorder
15.7.2.3.1.3. Obsessive
Compulsive Disorder
15.7.2.3.1.4. Generalized
Anxiety Disorder
15.7.2.3.1.5. Others
15.7.2.3.2. Depression
15.7.2.3.2.1. Major
Depression
15.7.2.3.2.2. Persistent
Depressive Disorder
15.7.2.3.2.3. Bipolar
Disorder
15.7.2.3.2.4. Others
15.7.2.4. Japan
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.7.2.4.1. Online
15.7.2.4.2. Offline
15.7.2.4.2.1. Hospitals/Clinics
15.7.2.4.2.2. Wellness
Centers
15.7.2.4.2.3. Research
Centers
15.7.2.4.2.4. Others
15.7.2.5. Japan
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
15.7.2.5.1. Children
15.7.2.5.2. Adults
15.7.2.5.3. Senior
Citizens
15.7.3. India
15.7.3.1. India
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
15.7.3.1.1. Products
15.7.3.1.1.1. Benzodiazepine
15.7.3.1.1.2. Buspirone
15.7.3.1.1.3. Beta
Blockers
15.7.3.1.1.3.1. Propranolol
15.7.3.1.1.3.2. Atenolol
15.7.3.1.1.3.3. Others
15.7.3.1.1.4. Others
15.7.3.1.2. Solutions
15.7.3.1.3. Services
15.7.3.1.3.1. Psychotherapy
15.7.3.1.3.1.1. Cognitive Behavioural Therapy (CBT)
15.7.3.1.3.1.2. Interpersonal Therapy (IPT)
15.7.3.1.3.1.3. Psychodynamic Therapy
15.7.3.1.3.1.4. Supportive Therapy
15.7.3.1.3.1.5. Others
15.7.3.1.3.2. Others
15.7.3.2. India
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
15.7.3.2.1. Short
Term
15.7.3.2.2. Long
Term
15.7.3.3. India
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
15.7.3.3.1. Anxiety
15.7.3.3.1.1. Panic
Disorder
15.7.3.3.1.2. Social
Anxiety Disorder
15.7.3.3.1.3. Obsessive
Compulsive Disorder
15.7.3.3.1.4. Generalized
Anxiety Disorder
15.7.3.3.1.5. Others
15.7.3.3.2. Depression
15.7.3.3.2.1. Major
Depression
15.7.3.3.2.2. Persistent
Depressive Disorder
15.7.3.3.2.3. Bipolar
Disorder
15.7.3.3.2.4. Others
15.7.3.4. India
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.7.3.4.1. Online
15.7.3.4.2. Offline
15.7.3.4.2.1. Hospitals/Clinics
15.7.3.4.2.2. Wellness
Centers
15.7.3.4.2.3. Research
Centers
15.7.3.4.2.4. Others
15.7.3.5. India
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
15.7.3.5.1. Children
15.7.3.5.2. Adults
15.7.3.5.3. Senior
Citizens
15.7.4. New
Zealand
15.7.4.1. New
Zealand Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Offerings
15.7.4.1.1. Products
15.7.4.1.1.1. Benzodiazepine
15.7.4.1.1.2. Buspirone
15.7.4.1.1.3. Beta
Blockers
15.7.4.1.1.3.1. Propranolol
15.7.4.1.1.3.2. Atenolol
15.7.4.1.1.3.3. Others
15.7.4.1.1.4. Others
15.7.4.1.2. Solutions
15.7.4.1.3. Services
15.7.4.1.3.1. Psychotherapy
15.7.4.1.3.1.1. Cognitive Behavioural Therapy (CBT)
15.7.4.1.3.1.2. Interpersonal Therapy (IPT)
15.7.4.1.3.1.3. Psychodynamic Therapy
15.7.4.1.3.1.4. Supportive Therapy
15.7.4.1.3.1.5. Others
15.7.4.1.3.2. Others
15.7.4.2. New
Zealand Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment Duration
15.7.4.2.1. Short
Term
15.7.4.2.2. Long
Term
15.7.4.3. New
Zealand Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Form
15.7.4.3.1. Anxiety
15.7.4.3.1.1. Panic
Disorder
15.7.4.3.1.2. Social
Anxiety Disorder
15.7.4.3.1.3. Obsessive
Compulsive Disorder
15.7.4.3.1.4. Generalized
Anxiety Disorder
15.7.4.3.1.5. Others
15.7.4.3.2. Depression
15.7.4.3.2.1. Major
Depression
15.7.4.3.2.2. Persistent
Depressive Disorder
15.7.4.3.2.3. Bipolar
Disorder
15.7.4.3.2.4. Others
15.7.4.4. New
Zealand Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
15.7.4.4.1. Online
15.7.4.4.2. Offline
15.7.4.4.2.1. Hospitals/Clinics
15.7.4.4.2.2. Wellness
Centers
15.7.4.4.2.3. Research
Centers
15.7.4.4.2.4. Others
15.7.4.5. New
Zealand Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Age Group
15.7.4.5.1. Children
15.7.4.5.2. Adults
15.7.4.5.3. Senior
Citizens
15.7.5. Australia
15.7.5.1. Australia
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
15.7.5.1.1. Products
15.7.5.1.1.1. Benzodiazepine
15.7.5.1.1.2. Buspirone
15.7.5.1.1.3. Beta
Blockers
15.7.5.1.1.3.1. Propranolol
15.7.5.1.1.3.2. Atenolol
15.7.5.1.1.3.3. Others
15.7.5.1.1.4. Others
15.7.5.1.2. Solutions
15.7.5.1.3. Services
15.7.5.1.3.1. Psychotherapy
15.7.5.1.3.1.1. Cognitive Behavioural Therapy (CBT)
15.7.5.1.3.1.2. Interpersonal Therapy (IPT)
15.7.5.1.3.1.3. Psychodynamic Therapy
15.7.5.1.3.1.4. Supportive Therapy
15.7.5.1.3.1.5. Others
15.7.5.1.3.2. Others
15.7.5.2. Australia
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
15.7.5.2.1. Short
Term
15.7.5.2.2. Long
Term
15.7.5.3. Australia
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
15.7.5.3.1. Anxiety
15.7.5.3.1.1. Panic
Disorder
15.7.5.3.1.2. Social
Anxiety Disorder
15.7.5.3.1.3. Obsessive
Compulsive Disorder
15.7.5.3.1.4. Generalized
Anxiety Disorder
15.7.5.3.1.5. Others
15.7.5.3.2. Depression
15.7.5.3.2.1. Major
Depression
15.7.5.3.2.2. Persistent
Depressive Disorder
15.7.5.3.2.3. Bipolar
Disorder
15.7.5.3.2.4. Others
15.7.5.4. Australia
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.7.5.4.1. Online
15.7.5.4.2. Offline
15.7.5.4.2.1. Hospitals/Clinics
15.7.5.4.2.2. Wellness
Centers
15.7.5.4.2.3. Research
Centers
15.7.5.4.2.4. Others
15.7.5.5. Australia
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
15.7.5.5.1. Children
15.7.5.5.2. Adults
15.7.5.5.3. Senior
Citizens
15.7.6. South
Korea
15.7.6.1. South
Korea Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Offerings
15.7.6.1.1. Products
15.7.6.1.1.1. Benzodiazepine
15.7.6.1.1.2. Buspirone
15.7.6.1.1.3. Beta
Blockers
15.7.6.1.1.3.1. Propranolol
15.7.6.1.1.3.2. Atenolol
15.7.6.1.1.3.3. Others
15.7.6.1.1.4. Others
15.7.6.1.2. Solutions
15.7.6.1.3. Services
15.7.6.1.3.1. Psychotherapy
15.7.6.1.3.1.1. Cognitive Behavioural Therapy (CBT)
15.7.6.1.3.1.2. Interpersonal Therapy (IPT)
15.7.6.1.3.1.3. Psychodynamic Therapy
15.7.6.1.3.1.4. Supportive Therapy
15.7.6.1.3.1.5. Others
15.7.6.1.3.2. Others
15.7.6.2. South
Korea Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment Duration
15.7.6.2.1. Short
Term
15.7.6.2.2. Long
Term
15.7.6.3. South
Korea Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Form
15.7.6.3.1. Anxiety
15.7.6.3.1.1. Panic
Disorder
15.7.6.3.1.2. Social
Anxiety Disorder
15.7.6.3.1.3. Obsessive
Compulsive Disorder
15.7.6.3.1.4. Generalized
Anxiety Disorder
15.7.6.3.1.5. Others
15.7.6.3.2. Depression
15.7.6.3.2.1. Major
Depression
15.7.6.3.2.2. Persistent
Depressive Disorder
15.7.6.3.2.3. Bipolar
Disorder
15.7.6.3.2.4. Others
15.7.6.4. South
Korea Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
15.7.6.4.1. Online
15.7.6.4.2. Offline
15.7.6.4.2.1. Hospitals/Clinics
15.7.6.4.2.2. Wellness
Centers
15.7.6.4.2.3. Research
Centers
15.7.6.4.2.4. Others
15.7.6.5. South
Korea Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Age Group
15.7.6.5.1. Children
15.7.6.5.2. Adults
15.7.6.5.3. Senior
Citizens
15.7.7. Southeast
Asia
15.7.7.1. Southeast
Asia Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
15.7.7.1.1. Products
15.7.7.1.1.1. Benzodiazepine
15.7.7.1.1.2. Buspirone
15.7.7.1.1.3. Beta
Blockers
15.7.7.1.1.3.1. Propranolol
15.7.7.1.1.3.2. Atenolol
15.7.7.1.1.3.3. Others
15.7.7.1.1.4. Others
15.7.7.1.2. Solutions
15.7.7.1.3. Services
15.7.7.1.3.1. Psychotherapy
15.7.7.1.3.1.1. Cognitive Behavioural Therapy (CBT)
15.7.7.1.3.1.2. Interpersonal Therapy (IPT)
15.7.7.1.3.1.3. Psychodynamic Therapy
15.7.7.1.3.1.4. Supportive Therapy
15.7.7.1.3.1.5. Others
15.7.7.1.3.2. Others
15.7.7.2. Southeast
Asia Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
15.7.7.2.1. Short
Term
15.7.7.2.2. Long
Term
15.7.7.3. Southeast
Asia Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Form
15.7.7.3.1. Anxiety
15.7.7.3.1.1. Panic
Disorder
15.7.7.3.1.2. Social
Anxiety Disorder
15.7.7.3.1.3. Obsessive
Compulsive Disorder
15.7.7.3.1.4. Generalized
Anxiety Disorder
15.7.7.3.1.5. Others
15.7.7.3.2. Depression
15.7.7.3.2.1. Major
Depression
15.7.7.3.2.2. Persistent
Depressive Disorder
15.7.7.3.2.3. Bipolar
Disorder
15.7.7.3.2.4. Others
15.7.7.4. Southeast
Asia Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.7.7.4.1. Online
15.7.7.4.2. Offline
15.7.7.4.2.1. Hospitals/Clinics
15.7.7.4.2.2. Wellness
Centers
15.7.7.4.2.3. Research
Centers
15.7.7.4.2.4. Others
15.7.7.5. Southeast
Asia Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Age Group
15.7.7.5.1. Children
15.7.7.5.2. Adults
15.7.7.5.3. Senior
Citizens
15.7.7.6. Southeast
Asia Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest
of Southeast Asia
15.7.8. Rest of
Asia Pacific
15.7.8.1. Rest
of Asia Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Offerings
15.7.8.1.1. Products
15.7.8.1.1.1. Benzodiazepine
15.7.8.1.1.2. Buspirone
15.7.8.1.1.3. Beta
Blockers
15.7.8.1.1.3.1. Propranolol
15.7.8.1.1.3.2. Atenolol
15.7.8.1.1.3.3. Others
15.7.8.1.1.4. Others
15.7.8.1.2. Solutions
15.7.8.1.3. Services
15.7.8.1.3.1. Psychotherapy
15.7.8.1.3.1.1. Cognitive Behavioural Therapy (CBT)
15.7.8.1.3.1.2. Interpersonal Therapy (IPT)
15.7.8.1.3.1.3. Psychodynamic Therapy
15.7.8.1.3.1.4. Supportive Therapy
15.7.8.1.3.1.5. Others
15.7.8.1.3.2. Others
15.7.8.2. Rest
of Asia Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment Duration
15.7.8.2.1. Short
Term
15.7.8.2.2. Long
Term
15.7.8.3. Rest
of Asia Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Form
15.7.8.3.1. Anxiety
15.7.8.3.1.1. Panic
Disorder
15.7.8.3.1.2. Social
Anxiety Disorder
15.7.8.3.1.3. Obsessive
Compulsive Disorder
15.7.8.3.1.4. Generalized
Anxiety Disorder
15.7.8.3.1.5. Others
15.7.8.3.2. Depression
15.7.8.3.2.1. Major
Depression
15.7.8.3.2.2. Persistent
Depressive Disorder
15.7.8.3.2.3. Bipolar
Disorder
15.7.8.3.2.4. Others
15.7.8.4. Rest
of Asia Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.7.8.4.1. Online
15.7.8.4.2. Offline
15.7.8.4.2.1. Hospitals/Clinics
15.7.8.4.2.2. Wellness
Centers
15.7.8.4.2.3. Research
Centers
15.7.8.4.2.4. Others
15.7.8.5. Rest
of Asia Pacific Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Age Group
15.7.8.5.1. Children
15.7.8.5.2. Adults
15.7.8.5.3. Senior
Citizens
15.8. Key
Segment for Channeling Investments
15.8.1. By
Country
15.8.2. By
Offerings
15.8.3. By
Treatment Duration
15.8.4. By Form
15.8.5. By
Distribution Channel
15.8.6. By Age
Group
16. Middle East and Africa Anxiety and Depression Treatment
Market Analysis and Forecasts, 2020 - 2028
16.1. Overview
16.1.1. Middle
East and Africa Anxiety and Depression Treatment Market Revenue (US$ Mn)
16.2. Middle
East and Africa Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Offerings
16.2.1. Products
16.2.1.1. Benzodiazepine
16.2.1.2. Buspirone
16.2.1.3. Beta
Blockers
16.2.1.3.1. Propranolol
16.2.1.3.2. Atenolol
16.2.1.3.3. Others
16.2.1.4. Others
16.2.2. Solutions
16.2.3. Services
16.2.3.1. Psychotherapy
16.2.3.1.1. Cognitive
Behavioural Therapy (CBT)
16.2.3.1.2. Interpersonal
Therapy (IPT)
16.2.3.1.3. Psychodynamic
Therapy
16.2.3.1.4. Supportive
Therapy
16.2.3.1.5. Others
16.2.3.2. Others
16.3. Middle
East and Africa Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment Duration
16.3.1. Short
Term
16.3.2. Long
Term
16.4. Middle
East and Africa Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Form
16.4.1. Anxiety
16.4.1.1. Panic
Disorder
16.4.1.2. Social
Anxiety Disorder
16.4.1.3. Obsessive
Compulsive Disorder
16.4.1.4. Generalized
Anxiety Disorder
16.4.1.5. Others
16.4.2. Depression
16.4.2.1. Major
Depression
16.4.2.2. Persistent
Depressive Disorder
16.4.2.3. Bipolar
Disorder
16.4.2.4. Others
16.5. Middle
East and Africa Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.5.1. Online
16.5.2. Offline
16.5.2.1. Hospitals/Clinics
16.5.2.2. Wellness
Centers
16.5.2.3. Research
Centers
16.5.2.4. Others
16.6. Middle
East and Africa Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Age Group
16.6.1. Children
16.6.2. Adults
16.6.3. Senior
Citizens
16.7. Middle
East and Africa Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Country
16.7.1. Saudi
Arabia
16.7.1.1. Saudi
Arabia Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Offerings
16.7.1.1.1. Products
16.7.1.1.1.1. Benzodiazepine
16.7.1.1.1.2. Buspirone
16.7.1.1.1.3. Beta
Blockers
16.7.1.1.1.3.1. Propranolol
16.7.1.1.1.3.2. Atenolol
16.7.1.1.1.3.3. Others
16.7.1.1.1.4. Others
16.7.1.1.2. Solutions
16.7.1.1.3. Services
16.7.1.1.3.1. Psychotherapy
16.7.1.1.3.1.1. Cognitive Behavioural Therapy (CBT)
16.7.1.1.3.1.2. Interpersonal Therapy (IPT)
16.7.1.1.3.1.3. Psychodynamic Therapy
16.7.1.1.3.1.4. Supportive Therapy
16.7.1.1.3.1.5. Others
16.7.1.1.3.2. Others
16.7.1.2. Saudi
Arabia Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment Duration
16.7.1.2.1. Short
Term
16.7.1.2.2. Long
Term
16.7.1.3. Saudi
Arabia Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Form
16.7.1.3.1. Anxiety
16.7.1.3.1.1. Panic
Disorder
16.7.1.3.1.2. Social
Anxiety Disorder
16.7.1.3.1.3. Obsessive
Compulsive Disorder
16.7.1.3.1.4. Generalized
Anxiety Disorder
16.7.1.3.1.5. Others
16.7.1.3.2. Depression
16.7.1.3.2.1. Major
Depression
16.7.1.3.2.2. Persistent
Depressive Disorder
16.7.1.3.2.3. Bipolar
Disorder
16.7.1.3.2.4. Others
16.7.1.4. Saudi
Arabia Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
16.7.1.4.1. Online
16.7.1.4.2. Offline
16.7.1.4.2.1. Hospitals/Clinics
16.7.1.4.2.2. Wellness
Centers
16.7.1.4.2.3. Research
Centers
16.7.1.4.2.4. Others
16.7.1.5. Saudi
Arabia Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Age Group
16.7.1.5.1. Children
16.7.1.5.2. Adults
16.7.1.5.3. Senior
Citizens
16.7.2. UAE
16.7.2.1. UAE
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
16.7.2.1.1. Products
16.7.2.1.1.1. Benzodiazepine
16.7.2.1.1.2. Buspirone
16.7.2.1.1.3. Beta
Blockers
16.7.2.1.1.3.1. Propranolol
16.7.2.1.1.3.2. Atenolol
16.7.2.1.1.3.3. Others
16.7.2.1.1.4. Others
16.7.2.1.2. Solutions
16.7.2.1.3. Services
16.7.2.1.3.1. Psychotherapy
16.7.2.1.3.1.1. Cognitive Behavioural Therapy (CBT)
16.7.2.1.3.1.2. Interpersonal Therapy (IPT)
16.7.2.1.3.1.3. Psychodynamic Therapy
16.7.2.1.3.1.4. Supportive Therapy
16.7.2.1.3.1.5. Others
16.7.2.1.3.2. Others
16.7.2.2. UAE
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
16.7.2.2.1. Short
Term
16.7.2.2.2. Long
Term
16.7.2.3. UAE
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
16.7.2.3.1. Anxiety
16.7.2.3.1.1. Panic
Disorder
16.7.2.3.1.2. Social
Anxiety Disorder
16.7.2.3.1.3. Obsessive
Compulsive Disorder
16.7.2.3.1.4. Generalized
Anxiety Disorder
16.7.2.3.1.5. Others
16.7.2.3.2. Depression
16.7.2.3.2.1. Major
Depression
16.7.2.3.2.2. Persistent
Depressive Disorder
16.7.2.3.2.3. Bipolar
Disorder
16.7.2.3.2.4. Others
16.7.2.4. UAE
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.7.2.4.1. Online
16.7.2.4.2. Offline
16.7.2.4.2.1. Hospitals/Clinics
16.7.2.4.2.2. Wellness
Centers
16.7.2.4.2.3. Research
Centers
16.7.2.4.2.4. Others
16.7.2.5. UAE
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
16.7.2.5.1. Children
16.7.2.5.2. Adults
16.7.2.5.3. Senior
Citizens
16.7.3. Egypt
16.7.3.1. Egypt
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
16.7.3.1.1. Products
16.7.3.1.1.1. Benzodiazepine
16.7.3.1.1.2. Buspirone
16.7.3.1.1.3. Beta
Blockers
16.7.3.1.1.3.1. Propranolol
16.7.3.1.1.3.2. Atenolol
16.7.3.1.1.3.3. Others
16.7.3.1.1.4. Others
16.7.3.1.2. Solutions
16.7.3.1.3. Services
16.7.3.1.3.1. Psychotherapy
16.7.3.1.3.1.1. Cognitive Behavioural Therapy (CBT)
16.7.3.1.3.1.2. Interpersonal Therapy (IPT)
16.7.3.1.3.1.3. Psychodynamic Therapy
16.7.3.1.3.1.4. Supportive Therapy
16.7.3.1.3.1.5. Others
16.7.3.1.3.2. Others
16.7.3.2. Egypt
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
16.7.3.2.1. Short
Term
16.7.3.2.2. Long
Term
16.7.3.3. Egypt
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
16.7.3.3.1. Anxiety
16.7.3.3.1.1. Panic
Disorder
16.7.3.3.1.2. Social
Anxiety Disorder
16.7.3.3.1.3. Obsessive
Compulsive Disorder
16.7.3.3.1.4. Generalized
Anxiety Disorder
16.7.3.3.1.5. Others
16.7.3.3.2. Depression
16.7.3.3.2.1. Major
Depression
16.7.3.3.2.2. Persistent
Depressive Disorder
16.7.3.3.2.3. Bipolar
Disorder
16.7.3.3.2.4. Others
16.7.3.4. Egypt
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.7.3.4.1. Online
16.7.3.4.2. Offline
16.7.3.4.2.1. Hospitals/Clinics
16.7.3.4.2.2. Wellness
Centers
16.7.3.4.2.3. Research
Centers
16.7.3.4.2.4. Others
16.7.3.5. Egypt
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
16.7.3.5.1. Children
16.7.3.5.2. Adults
16.7.3.5.3. Senior
Citizens
16.7.4. Kuwait
16.7.4.1. Kuwait
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
16.7.4.1.1. Products
16.7.4.1.1.1. Benzodiazepine
16.7.4.1.1.2. Buspirone
16.7.4.1.1.3. Beta
Blockers
16.7.4.1.1.3.1. Propranolol
16.7.4.1.1.3.2. Atenolol
16.7.4.1.1.3.3. Others
16.7.4.1.1.4. Others
16.7.4.1.2. Solutions
16.7.4.1.3. Services
16.7.4.1.3.1. Psychotherapy
16.7.4.1.3.1.1. Cognitive Behavioural Therapy (CBT)
16.7.4.1.3.1.2. Interpersonal Therapy (IPT)
16.7.4.1.3.1.3. Psychodynamic Therapy
16.7.4.1.3.1.4. Supportive Therapy
16.7.4.1.3.1.5. Others
16.7.4.1.3.2. Others
16.7.4.2. Kuwait
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
16.7.4.2.1. Short
Term
16.7.4.2.2. Long
Term
16.7.4.3. Kuwait
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
16.7.4.3.1. Anxiety
16.7.4.3.1.1. Panic
Disorder
16.7.4.3.1.2. Social
Anxiety Disorder
16.7.4.3.1.3. Obsessive
Compulsive Disorder
16.7.4.3.1.4. Generalized
Anxiety Disorder
16.7.4.3.1.5. Others
16.7.4.3.2. Depression
16.7.4.3.2.1. Major
Depression
16.7.4.3.2.2. Persistent
Depressive Disorder
16.7.4.3.2.3. Bipolar
Disorder
16.7.4.3.2.4. Others
16.7.4.4. Kuwait
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.7.4.4.1. Online
16.7.4.4.2. Offline
16.7.4.4.2.1. Hospitals/Clinics
16.7.4.4.2.2. Wellness
Centers
16.7.4.4.2.3. Research
Centers
16.7.4.4.2.4. Others
16.7.4.5. Kuwait
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
16.7.4.5.1. Children
16.7.4.5.2. Adults
16.7.4.5.3. Senior
Citizens
16.7.5. South
Africa
16.7.5.1. South
Africa Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Offerings
16.7.5.1.1. Products
16.7.5.1.1.1. Benzodiazepine
16.7.5.1.1.2. Buspirone
16.7.5.1.1.3. Beta
Blockers
16.7.5.1.1.3.1. Propranolol
16.7.5.1.1.3.2. Atenolol
16.7.5.1.1.3.3. Others
16.7.5.1.1.4. Others
16.7.5.1.2. Solutions
16.7.5.1.3. Services
16.7.5.1.3.1. Psychotherapy
16.7.5.1.3.1.1. Cognitive Behavioural Therapy (CBT)
16.7.5.1.3.1.2. Interpersonal Therapy (IPT)
16.7.5.1.3.1.3. Psychodynamic Therapy
16.7.5.1.3.1.4. Supportive Therapy
16.7.5.1.3.1.5. Others
16.7.5.1.3.2. Others
16.7.5.2. South
Africa Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment Duration
16.7.5.2.1. Short
Term
16.7.5.2.2. Long
Term
16.7.5.3. South
Africa Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Form
16.7.5.3.1. Anxiety
16.7.5.3.1.1. Panic
Disorder
16.7.5.3.1.2. Social
Anxiety Disorder
16.7.5.3.1.3. Obsessive
Compulsive Disorder
16.7.5.3.1.4. Generalized
Anxiety Disorder
16.7.5.3.1.5. Others
16.7.5.3.2. Depression
16.7.5.3.2.1. Major
Depression
16.7.5.3.2.2. Persistent
Depressive Disorder
16.7.5.3.2.3. Bipolar
Disorder
16.7.5.3.2.4. Others
16.7.5.4. South
Africa Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
16.7.5.4.1. Online
16.7.5.4.2. Offline
16.7.5.4.2.1. Hospitals/Clinics
16.7.5.4.2.2. Wellness
Centers
16.7.5.4.2.3. Research
Centers
16.7.5.4.2.4. Others
16.7.5.5. South
Africa Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Age Group
16.7.5.5.1. Children
16.7.5.5.2. Adults
16.7.5.5.3. Senior
Citizens
16.7.6. Rest of
Middle East & Africa
16.7.6.1. Rest
of Middle East & Africa Anxiety and Depression Treatment Market Revenue
(US$ Mn) and Forecasts, By Offerings
16.7.6.1.1. Products
16.7.6.1.1.1. Benzodiazepine
16.7.6.1.1.2. Buspirone
16.7.6.1.1.3. Beta
Blockers
16.7.6.1.1.3.1. Propranolol
16.7.6.1.1.3.2. Atenolol
16.7.6.1.1.3.3. Others
16.7.6.1.1.4. Others
16.7.6.1.2. Solutions
16.7.6.1.3. Services
16.7.6.1.3.1. Psychotherapy
16.7.6.1.3.1.1. Cognitive Behavioural Therapy (CBT)
16.7.6.1.3.1.2. Interpersonal Therapy (IPT)
16.7.6.1.3.1.3. Psychodynamic Therapy
16.7.6.1.3.1.4. Supportive Therapy
16.7.6.1.3.1.5. Others
16.7.6.1.3.2. Others
16.7.6.2. Rest
of Middle East & Africa Anxiety and Depression Treatment Market Revenue
(US$ Mn) and Forecasts, By Treatment Duration
16.7.6.2.1. Short
Term
16.7.6.2.2. Long
Term
16.7.6.3. Rest
of Middle East & Africa Anxiety and Depression Treatment Market Revenue
(US$ Mn) and Forecasts, By Form
16.7.6.3.1. Anxiety
16.7.6.3.1.1. Panic
Disorder
16.7.6.3.1.2. Social
Anxiety Disorder
16.7.6.3.1.3. Obsessive
Compulsive Disorder
16.7.6.3.1.4. Generalized
Anxiety Disorder
16.7.6.3.1.5. Others
16.7.6.3.2. Depression
16.7.6.3.2.1. Major
Depression
16.7.6.3.2.2. Persistent
Depressive Disorder
16.7.6.3.2.3. Bipolar
Disorder
16.7.6.3.2.4. Others
16.7.6.4. Rest
of Middle East & Africa Anxiety and Depression Treatment Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
16.7.6.4.1. Online
16.7.6.4.2. Offline
16.7.6.4.2.1. Hospitals/Clinics
16.7.6.4.2.2. Wellness
Centers
16.7.6.4.2.3. Research
Centers
16.7.6.4.2.4. Others
16.7.6.5. Rest
of Middle East & Africa Anxiety and Depression Treatment Market Revenue
(US$ Mn) and Forecasts, By Age Group
16.7.6.5.1. Children
16.7.6.5.2. Adults
16.7.6.5.3. Senior
Citizens
16.8. Key
Segment for Channeling Investments
16.8.1. By
Country
16.8.2. By
Offerings
16.8.3. By
Treatment Duration
16.8.4. By Form
16.8.5. By
Distribution Channel
16.8.6. By Age
Group
17. Latin America Anxiety and Depression Treatment Market
Analysis and Forecasts, 2020 - 2028
17.1. Overview
17.1.1. Latin
America Anxiety and Depression Treatment Market Revenue (US$ Mn)
17.2. Latin
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Offerings
17.2.1. Products
17.2.1.1. Benzodiazepine
17.2.1.2. Buspirone
17.2.1.3. Beta
Blockers
17.2.1.3.1. Propranolol
17.2.1.3.2. Atenolol
17.2.1.3.3. Others
17.2.1.4. Others
17.2.2. Solutions
17.2.3. Services
17.2.3.1. Psychotherapy
17.2.3.1.1. Cognitive
Behavioural Therapy (CBT)
17.2.3.1.2. Interpersonal
Therapy (IPT)
17.2.3.1.3. Psychodynamic
Therapy
17.2.3.1.4. Supportive
Therapy
17.2.3.1.5. Others
17.2.3.2. Others
17.3. Latin
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment Duration
17.3.1. Short
Term
17.3.2. Long
Term
17.4. Latin
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Form
17.4.1. Anxiety
17.4.1.1. Panic
Disorder
17.4.1.2. Social
Anxiety Disorder
17.4.1.3. Obsessive
Compulsive Disorder
17.4.1.4. Generalized
Anxiety Disorder
17.4.1.5. Others
17.4.2. Depression
17.4.2.1. Major
Depression
17.4.2.2. Persistent
Depressive Disorder
17.4.2.3. Bipolar
Disorder
17.4.2.4. Others
17.5. Latin
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
17.5.1. Online
17.5.2. Offline
17.5.2.1. Hospitals/Clinics
17.5.2.2. Wellness
Centers
17.5.2.3. Research
Centers
17.5.2.4. Others
17.6. Latin
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Age Group
17.6.1. Children
17.6.2. Adults
17.6.3. Senior
Citizens
17.7. Latin
America Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts,
By Country
17.7.1. Brazil
17.7.1.1. Brazil
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
17.7.1.1.1. Products
17.7.1.1.1.1. Benzodiazepine
17.7.1.1.1.2. Buspirone
17.7.1.1.1.3. Beta
Blockers
17.7.1.1.1.3.1. Propranolol
17.7.1.1.1.3.2. Atenolol
17.7.1.1.1.3.3. Others
17.7.1.1.1.4. Others
17.7.1.1.2. Solutions
17.7.1.1.3. Services
17.7.1.1.3.1. Psychotherapy
17.7.1.1.3.1.1. Cognitive Behavioural Therapy (CBT)
17.7.1.1.3.1.2. Interpersonal Therapy (IPT)
17.7.1.1.3.1.3. Psychodynamic Therapy
17.7.1.1.3.1.4. Supportive Therapy
17.7.1.1.3.1.5. Others
17.7.1.1.3.2. Others
17.7.1.2. Brazil
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
17.7.1.2.1. Short
Term
17.7.1.2.2. Long
Term
17.7.1.3. Brazil
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
17.7.1.3.1. Anxiety
17.7.1.3.1.1. Panic
Disorder
17.7.1.3.1.2. Social
Anxiety Disorder
17.7.1.3.1.3. Obsessive
Compulsive Disorder
17.7.1.3.1.4. Generalized
Anxiety Disorder
17.7.1.3.1.5. Others
17.7.1.3.2. Depression
17.7.1.3.2.1. Major
Depression
17.7.1.3.2.2. Persistent
Depressive Disorder
17.7.1.3.2.3. Bipolar
Disorder
17.7.1.3.2.4. Others
17.7.1.4. Brazil
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
17.7.1.4.1. Online
17.7.1.4.2. Offline
17.7.1.4.2.1. Hospitals/Clinics
17.7.1.4.2.2. Wellness
Centers
17.7.1.4.2.3. Research
Centers
17.7.1.4.2.4. Others
17.7.1.5. Brazil
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
17.7.1.5.1. Children
17.7.1.5.2. Adults
17.7.1.5.3. Senior
Citizens
17.7.2. Argentina
17.7.2.1. Argentina
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Offerings
17.7.2.1.1. Products
17.7.2.1.1.1. Benzodiazepine
17.7.2.1.1.2. Buspirone
17.7.2.1.1.3. Beta
Blockers
17.7.2.1.1.3.1. Propranolol
17.7.2.1.1.3.2. Atenolol
17.7.2.1.1.3.3. Others
17.7.2.1.1.4. Others
17.7.2.1.2. Solutions
17.7.2.1.3. Services
17.7.2.1.3.1. Psychotherapy
17.7.2.1.3.1.1. Cognitive Behavioural Therapy (CBT)
17.7.2.1.3.1.2. Interpersonal Therapy (IPT)
17.7.2.1.3.1.3. Psychodynamic Therapy
17.7.2.1.3.1.4. Supportive Therapy
17.7.2.1.3.1.5. Others
17.7.2.1.3.2. Others
17.7.2.2. Argentina
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment Duration
17.7.2.2.1. Short
Term
17.7.2.2.2. Long
Term
17.7.2.3. Argentina
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Form
17.7.2.3.1. Anxiety
17.7.2.3.1.1. Panic
Disorder
17.7.2.3.1.2. Social
Anxiety Disorder
17.7.2.3.1.3. Obsessive
Compulsive Disorder
17.7.2.3.1.4. Generalized
Anxiety Disorder
17.7.2.3.1.5. Others
17.7.2.3.2. Depression
17.7.2.3.2.1. Major
Depression
17.7.2.3.2.2. Persistent
Depressive Disorder
17.7.2.3.2.3. Bipolar
Disorder
17.7.2.3.2.4. Others
17.7.2.4. Argentina
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
17.7.2.4.1. Online
17.7.2.4.2. Offline
17.7.2.4.2.1. Hospitals/Clinics
17.7.2.4.2.2. Wellness
Centers
17.7.2.4.2.3. Research
Centers
17.7.2.4.2.4. Others
17.7.2.5. Argentina
Anxiety and Depression Treatment Market Revenue (US$ Mn) and Forecasts, By Age
Group
17.7.2.5.1. Children
17.7.2.5.2. Adults
17.7.2.5.3. Senior
Citizens
17.7.3. Rest of
Latin America
17.7.3.1. Rest
of Latin America Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Offerings
17.7.3.1.1. Products
17.7.3.1.1.1. Benzodiazepine
17.7.3.1.1.2. Buspirone
17.7.3.1.1.3. Beta
Blockers
17.7.3.1.1.3.1. Propranolol
17.7.3.1.1.3.2. Atenolol
17.7.3.1.1.3.3. Others
17.7.3.1.1.4. Others
17.7.3.1.2. Solutions
17.7.3.1.3. Services
17.7.3.1.3.1. Psychotherapy
17.7.3.1.3.1.1. Cognitive Behavioural Therapy (CBT)
17.7.3.1.3.1.2. Interpersonal Therapy (IPT)
17.7.3.1.3.1.3. Psychodynamic Therapy
17.7.3.1.3.1.4. Supportive Therapy
17.7.3.1.3.1.5. Others
17.7.3.1.3.2. Others
17.7.3.2. Rest of
Latin America Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment Duration
17.7.3.2.1. Short
Term
17.7.3.2.2. Long
Term
17.7.3.3. Rest
of Latin America Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Form
17.7.3.3.1. Anxiety
17.7.3.3.1.1. Panic
Disorder
17.7.3.3.1.2. Social
Anxiety Disorder
17.7.3.3.1.3. Obsessive
Compulsive Disorder
17.7.3.3.1.4. Generalized
Anxiety Disorder
17.7.3.3.1.5. Others
17.7.3.3.2. Depression
17.7.3.3.2.1. Major
Depression
17.7.3.3.2.2. Persistent
Depressive Disorder
17.7.3.3.2.3. Bipolar
Disorder
17.7.3.3.2.4. Others
17.7.3.4. Rest
of Latin America Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
17.7.3.4.1. Online
17.7.3.4.2. Offline
17.7.3.4.2.1. Hospitals/Clinics
17.7.3.4.2.2. Wellness
Centers
17.7.3.4.2.3. Research
Centers
17.7.3.4.2.4. Others
17.7.3.5. Rest
of Latin America Anxiety and Depression Treatment Market Revenue (US$ Mn) and
Forecasts, By Age Group
17.7.3.5.1. Children
17.7.3.5.2. Adults
17.7.3.5.3. Senior
Citizens
17.8. Key Segment
for Channeling Investments
17.8.1. By
Country
17.8.2. By
Offerings
17.8.3. By
Treatment Duration
17.8.4. By Form
17.8.5. By
Distribution Channel
17.8.6. By Age
Group
18. Competitive Benchmarking
18.1. Market
Share Analysis
18.2. Global
Presence and Growth Strategies
18.2.1. Mergers
and Acquisitions
18.2.2. Product
Launches
18.2.3. Investments
Trends
18.2.4. R&D
Initiatives
19. Player Profiles
19.1. Actiza
Pharmaceutical Private Limited
19.1.1. Company
Details
19.1.2. Company
Overview
19.1.3. Product
Offerings
19.1.4. Key
Developments
19.1.5. Financial
Analysis
19.1.6. SWOT
Analysis
19.1.7. Business
Strategies
19.2. Amwell
19.2.1. Company
Details
19.2.2. Company
Overview
19.2.3. Product
Offerings
19.2.4. Key
Developments
19.2.5. Financial
Analysis
19.2.6. SWOT
Analysis
19.2.7. Business
Strategies
19.3. ANI
Pharmaceuticals, Inc.
19.3.1. Company
Details
19.3.2. Company
Overview
19.3.3. Product
Offerings
19.3.4. Key
Developments
19.3.5. Financial
Analysis
19.3.6. SWOT
Analysis
19.3.7. Business
Strategies
19.4. BetterHelp
19.4.1. Company
Details
19.4.2. Company
Overview
19.4.3. Product
Offerings
19.4.4. Key
Developments
19.4.5. Financial
Analysis
19.4.6. SWOT
Analysis
19.4.7. Business
Strategies
19.5. eTherapyPro.com
19.5.1. Company
Details
19.5.2. Company
Overview
19.5.3. Product
Offerings
19.5.4. Key
Developments
19.5.5. Financial
Analysis
19.5.6. SWOT
Analysis
19.5.7. Business
Strategies
19.6. F.
Hoffmann-La Roche Ltd
19.6.1. Company
Details
19.6.2. Company
Overview
19.6.3. Product
Offerings
19.6.4. Key
Developments
19.6.5. Financial
Analysis
19.6.6. SWOT
Analysis
19.6.7. Business
Strategies
19.7. Groop
Internet Platform, Inc. (Talkspace)
19.7.1. Company
Details
19.7.2. Company
Overview
19.7.3. Product
Offerings
19.7.4. Key
Developments
19.7.5. Financial
Analysis
19.7.6. SWOT
Analysis
19.7.7. Business
Strategies
19.8. MDLIVE
Inc.
19.8.1. Company
Details
19.8.2. Company
Overview
19.8.3. Product
Offerings
19.8.4. Key
Developments
19.8.5. Financial
Analysis
19.8.6. SWOT
Analysis
19.8.7. Business
Strategies
19.9. Pfizer
Inc.
19.9.1. Company
Details
19.9.2. Company
Overview
19.9.3. Product
Offerings
19.9.4. Key
Developments
19.9.5. Financial
Analysis
19.9.6. SWOT
Analysis
19.9.7. Business
Strategies
19.10. Teva
Pharmaceuticals USA, Inc.
19.10.1. Company
Details
19.10.2. Company
Overview
19.10.3. Product
Offerings
19.10.4. Key
Developments
19.10.5. Financial
Analysis
19.10.6. SWOT
Analysis
19.10.7. Business
Strategies
19.11. The Ross
Center
19.11.1. Company
Details
19.11.2. Company
Overview
19.11.3. Product
Offerings
19.11.4. Key
Developments
19.11.5. Financial
Analysis
19.11.6. SWOT
Analysis
19.11.7. Business
Strategies
19.12. Other
Market Participants
20. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
![AMI AMI](https://www.absolutemarketsinsights.com/upload/Research_Scope2.jpg)
![AMI AMI](https://www.absolutemarketsinsights.com/upload/Global_IMG2.jpg)
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.
![AMI AMI](https://www.absolutemarketsinsights.com/images/iso_form.jpg)